Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting cabotegravir + rilpivirine for HIV infection in a real-world setting
ACTRN12622000105741Phase 4Completed
- Sponsor
- Royal Perth Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by Royal Perth Hospital. Primary endpoint: Adherence to long-acting therapy. Started Feb 2022; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12622000105741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000105741.